Market Access must support the business by interacting with a wide array of stakeholders within a complex decision-making framework, taking into account the stage of the product life cycle.
To define Market Access action priorities, we develop studies and projects that consider several key dimensions – target payers, product life cycle stage, and company goals.
In line with the adoption of therapy and patient management models, we analyze the responsibilities of regional and local decision-makers and their influence on decisions related to pharmaceutical spending and usage. This helps identify the significance of each target at different stages of the product life cycle.
